Ocular Hypertension (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension – Drugs In Development, 2021, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 13, 19, 3 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Angelini Spa

Betaliq Inc

Chong Kun Dang Holdings Corp

D. Western Therapeutics Institute Inc

Envisia Therapeutics Inc

Future Medicine Co Ltd

Glaukos Corp

Graybug Vision Inc

Ikarovec Ltd

Jenivision Inc

Kedalion Therapeutics Inc

Kowa Co Ltd

Laboratoires Thea SA

Laboratorios Sophia SA de CV

Lee's Pharmaceutical Holdings Ltd

MediPrint Ophthalmics Inc

Neurim Pharmaceuticals Ltd

NicOx SA

Noveome Biotherapeutics Inc

Ocular Therapeutix Inc

Ocuphire Pharma Inc

pH Pharma Co Ltd

Qlaris Bio Inc

Santen Pharmaceutical Co Ltd

Shenzhen Hornetcorn Bio-technology Company Ltd

Sun Pharma Advanced Research Company Ltd

Sun Pharmaceutical Industries Ltd

Sustained Nano Systems LLC

Sylentis SAU

TaeJoon Pharmaceuticals Co Ltd

ViSci Ltd

Whitecap Biosciences LLC

Table of Contents

Table of Contents

Introduction

Ocular Hypertension - Overview

Ocular Hypertension - Therapeutics Development

Ocular Hypertension - Therapeutics Assessment

Ocular Hypertension - Companies Involved in Therapeutics Development

Ocular Hypertension - Drug Profiles

Ocular Hypertension - Dormant Projects

Ocular Hypertension - Discontinued Products

Ocular Hypertension - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ocular Hypertension, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Ocular Hypertension – Pipeline by AbbVie Inc, 2021

Ocular Hypertension – Pipeline by Aerie Pharmaceuticals Inc, 2021

Ocular Hypertension – Pipeline by Aerpio Pharmaceuticals Inc, 2021

Ocular Hypertension – Pipeline by Angelini Spa, 2021

Ocular Hypertension – Pipeline by Betaliq Inc, 2021

Ocular Hypertension – Pipeline by Chong Kun Dang Holdings Corp, 2021

Ocular Hypertension – Pipeline by D. Western Therapeutics Institute Inc, 2021

Ocular Hypertension – Pipeline by Envisia Therapeutics Inc, 2021

Ocular Hypertension – Pipeline by Future Medicine Co Ltd, 2021

Ocular Hypertension – Pipeline by Glaukos Corp, 2021

Ocular Hypertension – Pipeline by Graybug Vision Inc, 2021

Ocular Hypertension – Pipeline by Ikarovec Ltd, 2021

Ocular Hypertension – Pipeline by Jenivision Inc, 2021

Ocular Hypertension – Pipeline by Kedalion Therapeutics Inc, 2021

Ocular Hypertension – Pipeline by Kowa Co Ltd, 2021

Ocular Hypertension – Pipeline by Laboratoires Thea SA, 2021

Ocular Hypertension – Pipeline by Laboratorios Sophia SA de CV, 2021

Ocular Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021

Ocular Hypertension – Pipeline by MediPrint Ophthalmics Inc, 2021

Ocular Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, 2021

Ocular Hypertension – Pipeline by NicOx SA, 2021

Ocular Hypertension – Pipeline by Noveome Biotherapeutics Inc, 2021

Ocular Hypertension – Pipeline by Ocular Therapeutix Inc, 2021

Ocular Hypertension – Pipeline by Ocuphire Pharma Inc, 2021

Ocular Hypertension – Pipeline by pH Pharma Co Ltd, 2021

Ocular Hypertension – Pipeline by Qlaris Bio Inc, 2021

Ocular Hypertension – Pipeline by Santen Pharmaceutical Co Ltd, 2021

Ocular Hypertension – Pipeline by Shenzhen Hornetcorn Bio-technology Company Ltd, 2021

Ocular Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, 2021

Ocular Hypertension – Pipeline by Sun Pharmaceutical Industries Ltd, 2021

Ocular Hypertension – Pipeline by Sustained Nano Systems LLC, 2021

Ocular Hypertension – Pipeline by Sylentis SAU, 2021

Ocular Hypertension – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2021

Ocular Hypertension – Pipeline by ViSci Ltd, 2021

Ocular Hypertension – Pipeline by Whitecap Biosciences LLC, 2021

Ocular Hypertension – Dormant Projects, 2021

Ocular Hypertension – Dormant Projects, 2021 (Contd..1)

Ocular Hypertension – Dormant Projects, 2021 (Contd..2)

Ocular Hypertension – Discontinued Products, 2021

Ocular Hypertension – Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Ocular Hypertension, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports